The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis

Endocrine Journal

Volumn 53, Issue 1, 2006, Pages 27-34

  Kaji, Hiroshi ^a   Yamauchi, Mika ^b   Chihara, Kazuo ^a   Sugimoto, Toshitsugu ^b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

Author keywords

Bone mineral density; Fracture threshold; Glucocorticoid; Osteoporosis; Vertebral fracture

Indexed keywords

GLUCOCORTICOID; PREDNISOLONE;

ADULT; AGE DISTRIBUTION; ANALYTIC METHOD; ARTICLE; AUTOIMMUNE DISEASE; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; INCIDENCE; LUMBAR SPINE; MAJOR CLINICAL STUDY; RADIUS; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VERTEBRA FRACTURE;

AGED; AGING; AUTOIMMUNE DISEASES; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; CASE-CONTROL STUDIES; DENSITOMETRY, X-RAY; FEMALE; FEMORAL NECK FRACTURES; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; INCIDENCE; LUMBAR VERTEBRAE; LUNG DISEASES; MIDDLE AGED; NERVOUS SYSTEM DISEASES; OSTEOPOROSIS; RADIUS FRACTURES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SKIN DISEASES; SPINAL INJURIES;

EID: 33645014782     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.53.27     Document Type: Article

References (37)

1. Ross EJ, Linch DC (1982) Cushing's syndrome-killing disease: discrimininatory value of signs and symptoms aiding early diagnosis. Lancet 2: 646-649.
2. Adinoff AD, Hollister JR (1983) Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309: 265-268.
3. Ohmori N, Nomura K, Ohmori K, Kato Y, Itoh T, Takano K (2003) Osteoporosis is more prevalent in adrenal than in pituitary Cushing's syndrome. Endocr J 50: 1-7.
4. Bressot C, Meunier J, Lejeune E, Edouard C, Darby A (1979) Histomorphometric profile, pathophysiology and reversibility of of glucocorticoid-induced osteoporosis. Metab Bone Dis Rel Res 1: 303-311.
5. Canalis E (1996) Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 81: 3441-3447.
6. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15: 993-1000.
7. Steinbuch M, Youket TE, Cohen S (2004) Oral glucocorticoid use is associated with an increased risk of fracture. Osteopors Int 15: 323-328.
8. Kanis JA, Johansson H, Oden Am Johnell O, de Laet C, Melton III LJ, Tenenhouse A, Reeve J, Silman AJ, Pols HAP, Eisman JA, McCloskey EV, Mellstrom D (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19: 893-899.
9. Van Staa TP, Leufkens HGM, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteopors Int 13: 777-787.
10. Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J (1991) Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 46: 803-806.
11. Laan RF, van Riel PL, van Erning LJ, Lemmens JA, Ruijs SH, van de Putte LB (1992) Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy. Brit J Rheumatol 31: 91-96.
12. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1995) Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 22: 1155-1159.
13. Laan RF, van Riel PL, van de Putte LB, van Eming LJ, van Hof MA, Lemmens JA (1993) Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: a randomized, controlled study. Ann Int Med 119: 963-968.
14. Sambrook P, Birmingham J, Kempler S, Kelly P, Eberl S, Pecock N, Yeates M, Eisman J (1990) Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 5: 1211-1216.
15. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R (1995) Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheu Dis 54: 801-806.
16. Selby PL, Halsey JP, Adams KRH, Klimiuk P, Knight SM, Pal B, Stewart IM, Swinson DR (2000) Corticosteroids do not alter the threshold for vertebral fracture. J Bone Miner Res 15: 952-956.
17. Tsugeno H, Fujita T, Goto B, Sugishita T, Hosaki Y, Ashida K, Mitsunobu F, Tanizaki Y, Shiratori Y (2002) Vertebral fracture and cortical bone changes in corticosteroid-induced osteoporosis. Osteopors Int 13: 650-656.
18. Wallach S, Cohen S, Reid DM, Highes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcifi Tis Int 67: 277-285.
19. Chen Q, Kaji H, Iu MF, Nomura R, Sowa H, Yamauchi M, Tsukamoto T, Sugimoto T, Chihara K (2003) Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab 88: 2655-4658.
20. Nakaoka D, Sugimoto T, Kaji H, Kanzawa M, Yano S, Yamauchi M, Sugishita T, Chihara K (2001) Determinants of bone mineral density and spinal fracture risk in postmenopausal Japanese women. Osteopors Int 12: 548-554.
21. Smith-Bindman R, Cummings SR, Steiger P, Genant HK (1991) A comparison of morphometric definitions of vertebral fractures. J Bone Miner Res 6: 25-34.
22. Hanley JA, McNail BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36.
23. Michel BA, Bloch DA, Wolfe F, Fries JF (1993) Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 20: 1666-1669.
24. Ramsey-Goldman R, Dunn JE, Huang CF, Dunlop P, Rairie JE, Fitzgerald S, Manzi S (1999) Frequency for fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthr Rheum 42: 882-890.
25. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthr Rheum 48: 3224-3229.
26. NIH Consensus Development Panel on Osteoporosis Prevention (2001) Osteoporosis prevention, diagnosis, and the therapy. JAMA 285: 785-795.
27. Prummel MF, Wiersinga WM, Lips P, Sanders TB, Sauerwein HP (1991) The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 72: 382-386.
28. Osella G, Terzolo M, Reimondo G, Piovesan A, Pia A, Termine A, Paccotti P, Angeli A (1991) Serum markers of bone and collagen turnover in patients with Cushing's syndrome and in subjects with adrenal incidentalomas. J Clin Endocrinol Metab 82: 3303-3307.
29. Chapard D, Legerand E, Basle MF, Fromont P, Racineux JL, Rebel A, Audran M (1996) Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 11: 676-685.
30. Carbonare LD, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ (2001) Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16: 97-103.
31. Aaron JE, Francis RM, Peacock M, Makins NB (1989) Contrasting microanatomy of idiopathic and corticosteroid-induced osteoporosis. Clin Orthoped 243: 294-305.
32. Weistein RS, Jika RL, Parfitt AM, Manolagas SC (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102: 274-282.
33. Smith E, Redman RA, Logg CR, Coetzee GA, Kasahara N, Frenkel B (2000) Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle. Dissociation of cyclin A-dependent kinase 2 from E2F4-p130 complexes. J Biol Chem 275: 19992-20001.
34. Manolagas SC (2000) Corticosteroids and fractures: close encounter of the third cell kind. J Bone Miner Res 15: 1001-1005.
35. Yamauchi M, Sugimoto T, Chihara K (2004) Determinants of vertebral fragility: the participation of cortical bone factors. J Bone Miner Metab 22: 79-85.
36. Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y (2005) Guldelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research. J Bone Miner Metab 23: 105-109.
37. Tanaka I, Oshima H (2003) A longitudinal study of diagnosis and treatment for glucocorticoid-induced osteoporosis. Osteoporosis Jpn 11: 11-14.